Spyre Therapeutics (SYRE) Competitors

Spyre Therapeutics has lower revenue, but higher earnings than Insmed. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Insmed currently has a consensus target price of $200.57, indicating a potential upside of 80.49%. Spyre Therapeutics has a consensus target price of $109.71, indicating a potential upside of 17.73%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts plainly believe Insmed is more favorable than Spyre Therapeutics.

Spyre Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Spyre Therapeutics' return on equity of -30.74% beat Insmed's return on equity.

80.4% of Spyre Therapeutics shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Spyre Therapeutics had 19 more articles in the media than Insmed. MarketBeat recorded 24 mentions for Spyre Therapeutics and 5 mentions for Insmed. Insmed's average media sentiment score of 0.53 beat Spyre Therapeutics' score of 0.27 indicating that Insmed is being referred to more favorably in the media.

Insmed has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.1, meaning that its stock price is 210% more volatile than the broader market.

In the previous week, Spyre Therapeutics and Spyre Therapeutics both had 24 articles in the media. Incyte's average media sentiment score of 0.65 beat Spyre Therapeutics' score of 0.27 indicating that Incyte is being referred to more favorably in the news media.

Incyte has a net margin of 27.71% compared to Spyre Therapeutics' net margin of 0.00%. Incyte's return on equity of 29.93% beat Spyre Therapeutics' return on equity.

Spyre Therapeutics has a beta of 3.1, meaning that its share price is 210% more volatile than the broader market. Comparatively, Incyte has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Spyre Therapeutics presently has a consensus price target of $109.71, suggesting a potential upside of 17.73%. Incyte has a consensus price target of $126.15, suggesting a potential upside of 9.41%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than Incyte.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Incyte has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

In the previous week, Spyre Therapeutics had 1 more articles in the media than BioNTech. MarketBeat recorded 24 mentions for Spyre Therapeutics and 23 mentions for BioNTech. Spyre Therapeutics' average media sentiment score of 0.27 beat BioNTech's score of 0.16 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Spyre Therapeutics has a beta of 3.1, meaning that its share price is 210% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

Spyre Therapeutics has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Spyre Therapeutics' return on equity.

Spyre Therapeutics presently has a consensus price target of $109.71, suggesting a potential upside of 17.73%. BioNTech has a consensus price target of $126.00, suggesting a potential upside of 30.03%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Spyre Therapeutics.

Spyre Therapeutics has higher earnings, but lower revenue than BioNTech. Spyre Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Spyre Therapeutics had 17 more articles in the media than Genmab A/S. MarketBeat recorded 24 mentions for Spyre Therapeutics and 7 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.36 beat Spyre Therapeutics' score of 0.27 indicating that Genmab A/S is being referred to more favorably in the media.

Genmab A/S has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Genmab A/S has a net margin of 19.08% compared to Spyre Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Spyre Therapeutics' return on equity.

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Genmab A/S has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.1, suggesting that its share price is 210% more volatile than the broader market.

Genmab A/S currently has a consensus price target of $39.50, suggesting a potential upside of 13.67%. Spyre Therapeutics has a consensus price target of $109.71, suggesting a potential upside of 17.73%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Spyre Therapeutics is more favorable than Genmab A/S.